Or Yat Sun

SEC source: 0002064832-26-000008 · form4.xml · nonDerivative · entry 3

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,854

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0002064832-26-000008 · form4.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 378,267

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026.

SEC source: 0002064832-26-000008 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 373,042

F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026.

SEC source: 0002064832-25-000059 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,392

F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0002064832-25-000044 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 373,782

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.

SEC source: 0002064832-25-000026 · form4.xml · derivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2035-11-25

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025).

SEC source: 0001062993-25-002558 · form4.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,535

F2 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.

SEC source: 0001062993-25-002558 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 378,859

F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.

SEC source: 0001062993-24-020380 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 369,109

F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.

SEC source: 0001062993-24-019982 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,700

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 20, 2020 and November 19, 2021.

SEC source: 0001062993-24-019768 · form4.xml · derivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,000

Underlying: Common Stock · 87,000 shares

Expires 2034-11-27

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

SEC source: 0001062993-24-003229 · form4.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 373,295

F2 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU awards.

SEC source: 0001062993-24-003229 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,375

F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2022-2023 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2024.

SEC source: 0001062993-23-022049 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP, R&D & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 370,695

F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.48 to $9.63, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.

SEC source: 0001062993-23-021985 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP, R&D & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 373,107

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 20, 2020 and November 19, 2021.

SEC source: 0001062993-23-021381 · form4.xml · derivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP, R&D & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,000

Underlying: Common Stock · 86,000 shares

Expires 2033-11-22

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023).

SEC source: 0001062993-23-007221 · form4.xml · derivative · entry 4

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,925 shares

Expires 2023-03-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: On March 21, 2013, the reporting person was granted an option to purchase 41,763 shares of common stock, half of which became exercisable upon the achievement of several clinical milestones during the four-year performance period after the date of grant.

SEC source: 0001062993-23-007221 · form4.xml · nonDerivative · entry 3

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 374,702

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in November 2022.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.02 to $45.00, inclusive.

SEC source: 0001062993-23-007221 · form4.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 388,358

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in November 2022.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.86 to $43.96, inclusive.

SEC source: 0001062993-23-007221 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 388,627

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-23-003715 · form4.xml · nonDerivative · entry 3

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 374,702

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001062993-23-003715 · form4.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 382,454

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 18, 2020 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 13, 2023.

SEC source: 0001062993-23-003715 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,437

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 18, 2020 that vested as a result of the achievement of a research and development milestone in calendar 2022 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 13, 2023.

SEC source: 0001062993-22-023363 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 359,187

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 20, 2020 and November 19, 2021.

SEC source: 0001062993-22-022846 · form4.xml · derivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2032-11-23

F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 23, 2022).

SEC source: 0001062993-22-022846 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 360,242

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle with respect to 25% of the award on December 4, 2023 and in substantially equal annual installments over the next three anniversaries thereafter.

SEC source: 0001062993-22-004514 · form4.xml · nonDerivative · entry 3

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,242

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001062993-22-004514 · form4.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 340,195

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004514 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,776

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-21-012201 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,161

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 20, 2020.

SEC source: 0001062993-21-011504 · form4.xml · derivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,400

Underlying: Common Stock · 28,400 shares

Expires 2031-11-19

F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

SEC source: 0001062993-21-011504 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,718

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.

SEC source: 0001177648-21-000008 · edgar.xml · derivative · entry 6

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,872 shares

Expires 2022-06-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-21-000008 · edgar.xml · derivative · entry 5

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,672 shares

Expires 2022-06-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-21-000008 · edgar.xml · derivative · entry 4

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,149 shares

Expires 2022-12-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-21-000008 · edgar.xml · nonDerivative · entry 3

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 330,918

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-21-000008 · edgar.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 326,046

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-21-000008 · edgar.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,374

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-20-000053 · edgar.xml · derivative · entry 3

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Restricted stock units convert into ENTA common stock on a one-for-one basis.

F4 · derivative.exercise_date: On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units have previously vested and the remainder vested on November 18, 2020.

F4 · derivative.expiration_date: On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units have previously vested and the remainder vested on November 18, 2020.

SEC source: 0001177648-20-000053 · edgar.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 317,225

F3 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award.

SEC source: 0001177648-20-000053 · edgar.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,765

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2020. The settlement and issuance of the shares was subject to continued employment and occurred on December 15, 2020.

F2 · price: Restricted stock units convert into ENTA common stock on a one-for-one basis.

SEC source: 0001177648-20-000039 · edgar.xml · derivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,800

Underlying: Common Stock · 30,800 shares

Expires 2030-11-20

F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020).

SEC source: 0001177648-20-000039 · edgar.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 313,515

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 20, 2020). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.

SEC source: 0001177648-20-000008 · edgar.xml · nonDerivative · entry 3

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,915

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001177648-20-000008 · edgar.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,004

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on March 1, 2018 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2020.

SEC source: 0001177648-20-000008 · edgar.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,079

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on March 1, 2018 that vested as a result of the achievement of a research and development milestone in calendar 2019 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2020.

SEC source: 0001177648-20-000003 · edgar.xml · derivative · entry 3

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,250

Underlying: Common Stock · 5,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Restricted stock units convert into ENTA common stock on a one-for-one basis.

F4 · derivative.exercise_date: On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units vested on November 18, 2019 and the remainder will vest on November 18, 2020, subject to the reporting person's continued employment.

F4 · derivative.expiration_date: On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units vested on November 18, 2019 and the remainder will vest on November 18, 2020, subject to the reporting person's continued employment.

SEC source: 0001177648-20-000003 · edgar.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 303,592

F3 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award.

SEC source: 0001177648-20-000003 · edgar.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,923

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2019. The settlement and issuance of the shares was subject to continued employment and occurred on December 16, 2019.

F2 · price: Restricted stock units convert into ENTA common stock on a one-for-one basis.

SEC source: 0001177648-19-000040 · edgar.xml · derivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2029-11-18

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019).